Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products Administration (NMPA) to initiate clinical studies for its two Category 1 chemical drugs, HRS-1738 and HRS-5817, targeting prostate cancer and overweight/obesity respectively.
HRS-1738: Prostate Cancer Diagnostic Innovation
HRS-1738 is an internally developed radiopharmaceutical designed for in vivo diagnostics. It is suitable for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in prostate cancer patients, offering a novel tool for precise diagnostics in this field.
HRS-5817: Weight Loss Solution
HRS-5817 is a self-developed weight loss drug. Pre-clinical trials demonstrated significant weight loss effects in obese animal models alongside good safety profiles. This positions HRS-5817 as a promising candidate in the global fight against obesity.
Global Innovation Lead
Neither HRS-1738 nor HRS-5817 has comparable approved drugs globally, highlighting Hengrui’s innovative capabilities and potential to set new standards in their respective therapeutic areas.-Fineline Info & Tech
Leave a Reply